Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 1 Neoplasms by Histologic Type 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia 1 Hematologic Diseases 1 Granulosa Cell Tumor 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Bone Marrow Diseases 1 Advanced Solid Tumor 1

Interventions

pembrolizumab 30 Capecitabine 24 Bevacizumab 23 Cyclophosphamide 22 Gemcitabine 21 Paclitaxel 20 Nivolumab 19 Fluorouracil 19 Docetaxel 18 aldesleukin 17 Leucovorin 17 Irinotecan 17 Oxaliplatin 15 Interleukin-2 14 Radiosurgery 13 Cisplatin 13 Cetuximab 13 fludarabine 12 Carboplatin 12 Albumin-Bound Paclitaxel 11 fludarabine phosphate 10 Ipilimumab 10 Drug Therapy 10 Doxorubicin 10 Sunitinib 9 Radiotherapy 9 Everolimus 9 130-nm albumin-bound paclitaxel 9 Trastuzumab 8 Temozolomide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasm Metastasis × BID protein, human × Clear all

NCT02101684 2018-03-05

Greko II

Grupo Español de Tumores Huérfanos e Infrecuentes

Phase 2 Terminated

Granulosa Cell Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡